TY  - CONF
AU  - Đorđević, J.
AU  - Mitrović, M.
AU  - Marinković, Valentina
AU  - Tasić, Ljiljana
AU  - Krajnović, Dušanka
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2109
AB  - Objectives: Colistimethate sodium (Colistin) is an old, “forgotten” antibiotics
revived due to multidrug-resistant Gram-negative bacteria in nosocomial infec-
tions. In many countries, both – intravenous and inhalational administrations of
Colistin have marketing authorisation. In Serbia, Colistin is registered only for
intravenous administration. Therefore, inhalational administration of Colistin in
treatment for cystic fibrosis is considered as off label use. AiM: The purpose of
this study was to assess benefits of Colistin off label use, currently available in
Serbia, for treatment for cystic fibrosis. MethOds: Data collected from a review
of the literature (Pubmed searching key word off label, Colistin, Tobramycine, cost
minimisation) and data from Health Insurance Fond of Republic Serbia (2014)
were used to perform a cost-minimisation analysis comparing DDD in inhalation
administration of Colistin with Tobramycin (official methodology in Serbia for drug
reimbursement Listing). Results: Both, Colistin and Tobramycine are effective
in cystic fibrosis treatment. The cost of treatment per patient per year in Serbia is
3 616,00 Euro for Colistin and 5 950,00 Euro for Tobramycin. Total savings per year
for 200 registered patients in Serbia could be 466 857,00 Euro. cOnclusiOns:
Given cost-minimisation analysis justified the treatment with Colistin as cost
saving therapeutic alternative to Tobramycin for cystic fibrosis patients in Serbia.
The lack of guidelines and principles regarding off label medicine use in health
care policy and decision making in Serbia was evidently an obstacle for better
patients care.
PB  - Elsevier Science Inc
C3  - Value in Health
T1  - Cost-Minimisation Analysis of Colistimethate Sodium in Serbia- off Label Use Approach
VL  - 17
IS  - 7
SP  - A399
EP  - A399
DO  - 10.1016/j.jval.2014.08.904
ER  - 

@conference{
author = "Đorđević, J. and Mitrović, M. and Marinković, Valentina and Tasić, Ljiljana and Krajnović, Dušanka",
year = "2014",
abstract = "Objectives: Colistimethate sodium (Colistin) is an old, “forgotten” antibiotics
revived due to multidrug-resistant Gram-negative bacteria in nosocomial infec-
tions. In many countries, both – intravenous and inhalational administrations of
Colistin have marketing authorisation. In Serbia, Colistin is registered only for
intravenous administration. Therefore, inhalational administration of Colistin in
treatment for cystic fibrosis is considered as off label use. AiM: The purpose of
this study was to assess benefits of Colistin off label use, currently available in
Serbia, for treatment for cystic fibrosis. MethOds: Data collected from a review
of the literature (Pubmed searching key word off label, Colistin, Tobramycine, cost
minimisation) and data from Health Insurance Fond of Republic Serbia (2014)
were used to perform a cost-minimisation analysis comparing DDD in inhalation
administration of Colistin with Tobramycin (official methodology in Serbia for drug
reimbursement Listing). Results: Both, Colistin and Tobramycine are effective
in cystic fibrosis treatment. The cost of treatment per patient per year in Serbia is
3 616,00 Euro for Colistin and 5 950,00 Euro for Tobramycin. Total savings per year
for 200 registered patients in Serbia could be 466 857,00 Euro. cOnclusiOns:
Given cost-minimisation analysis justified the treatment with Colistin as cost
saving therapeutic alternative to Tobramycin for cystic fibrosis patients in Serbia.
The lack of guidelines and principles regarding off label medicine use in health
care policy and decision making in Serbia was evidently an obstacle for better
patients care.",
publisher = "Elsevier Science Inc",
journal = "Value in Health",
title = "Cost-Minimisation Analysis of Colistimethate Sodium in Serbia- off Label Use Approach",
volume = "17",
number = "7",
pages = "A399-A399",
doi = "10.1016/j.jval.2014.08.904"
}

Đorđević, J., Mitrović, M., Marinković, V., Tasić, L.,& Krajnović, D.. (2014). Cost-Minimisation Analysis of Colistimethate Sodium in Serbia- off Label Use Approach. in Value in Health
Elsevier Science Inc., 17(7), A399-A399.
https://doi.org/10.1016/j.jval.2014.08.904

Đorđević J, Mitrović M, Marinković V, Tasić L, Krajnović D. Cost-Minimisation Analysis of Colistimethate Sodium in Serbia- off Label Use Approach. in Value in Health. 2014;17(7):A399-A399.
doi:10.1016/j.jval.2014.08.904 .

Đorđević, J., Mitrović, M., Marinković, Valentina, Tasić, Ljiljana, Krajnović, Dušanka, "Cost-Minimisation Analysis of Colistimethate Sodium in Serbia- off Label Use Approach" in Value in Health, 17, no. 7 (2014):A399-A399,
https://doi.org/10.1016/j.jval.2014.08.904 . .

TY  - JOUR
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
AU  - Mitrović, M.
AU  - Gvozdenović, Miomir
PY  - 2000
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/241
AB  - In this study we determined the clinical accuracy of alpha (2)-macroglobulin, alpha -amylase, C-reactive protein, lipase, non-esterified fatty acids, pancreatic alpha -amylase and phospholipase A in the diagnosis and prognosis of acute pancreatitis in a group of patients with acute abdominal pain using receiver operator characteristic curve analysis. We investigated 59 patients with acute pancreatitis and 72 patients with extrapancreatic diseases of gastrointestinal origin. On the basis of initial enzyme activities, at cut-offs of 245 U/I for amylase. 656 U/I for lipase, and 182 U/I for pancreatic alpha -amylase, the diagnostic efficiencies were 0.993, 0.980, and 0.975, respectively. Receiver operator characteristic curve analysis showed the same diagnostic accuracies. We evaluated the accuracy of serum alpha (2)-macroglobulin, C-reactive protein, non-esterified fatty acids end phospholipase A for differentiation between acute necrotizing pancreatitis and acute oedematous pancreatitis. C-reactive protein had the highest prognostic accuracy of the parameters studied (the area under curve = 0.9082) and at a cut-off value of 126 mg/l, sensitivity and specificity were 0.759 and 0.912, respectively. The role of the clinical laboratory in the investigation of patients with acute pancreatitis continues to evolve and biochemical parameters are a good diagnostic and prognostic: option.
PB  - Walter de Gruyter & Co, Berlin
T2  - Clinical Chemistry and Laboratory Medicine
T1  - Biochemical evaluation of patients with acute pancreatitis
VL  - 38
IS  - 11
SP  - 1141
EP  - 1144
DO  - 10.1515/CCLM.2000.173
ER  - 

@article{
author = "Ignjatović, Svetlana and Majkić-Singh, Nada and Mitrović, M. and Gvozdenović, Miomir",
year = "2000",
abstract = "In this study we determined the clinical accuracy of alpha (2)-macroglobulin, alpha -amylase, C-reactive protein, lipase, non-esterified fatty acids, pancreatic alpha -amylase and phospholipase A in the diagnosis and prognosis of acute pancreatitis in a group of patients with acute abdominal pain using receiver operator characteristic curve analysis. We investigated 59 patients with acute pancreatitis and 72 patients with extrapancreatic diseases of gastrointestinal origin. On the basis of initial enzyme activities, at cut-offs of 245 U/I for amylase. 656 U/I for lipase, and 182 U/I for pancreatic alpha -amylase, the diagnostic efficiencies were 0.993, 0.980, and 0.975, respectively. Receiver operator characteristic curve analysis showed the same diagnostic accuracies. We evaluated the accuracy of serum alpha (2)-macroglobulin, C-reactive protein, non-esterified fatty acids end phospholipase A for differentiation between acute necrotizing pancreatitis and acute oedematous pancreatitis. C-reactive protein had the highest prognostic accuracy of the parameters studied (the area under curve = 0.9082) and at a cut-off value of 126 mg/l, sensitivity and specificity were 0.759 and 0.912, respectively. The role of the clinical laboratory in the investigation of patients with acute pancreatitis continues to evolve and biochemical parameters are a good diagnostic and prognostic: option.",
publisher = "Walter de Gruyter & Co, Berlin",
journal = "Clinical Chemistry and Laboratory Medicine",
title = "Biochemical evaluation of patients with acute pancreatitis",
volume = "38",
number = "11",
pages = "1141-1144",
doi = "10.1515/CCLM.2000.173"
}

Ignjatović, S., Majkić-Singh, N., Mitrović, M.,& Gvozdenović, M.. (2000). Biochemical evaluation of patients with acute pancreatitis. in Clinical Chemistry and Laboratory Medicine
Walter de Gruyter & Co, Berlin., 38(11), 1141-1144.
https://doi.org/10.1515/CCLM.2000.173

Ignjatović S, Majkić-Singh N, Mitrović M, Gvozdenović M. Biochemical evaluation of patients with acute pancreatitis. in Clinical Chemistry and Laboratory Medicine. 2000;38(11):1141-1144.
doi:10.1515/CCLM.2000.173 .

Ignjatović, Svetlana, Majkić-Singh, Nada, Mitrović, M., Gvozdenović, Miomir, "Biochemical evaluation of patients with acute pancreatitis" in Clinical Chemistry and Laboratory Medicine, 38, no. 11 (2000):1141-1144,
https://doi.org/10.1515/CCLM.2000.173 . .